Tonus 2013 Ltd.

Research site

Bulgaria Bulevard Tsar Osvoboditel 41, 4400 Pazardzhik, Bulgaria

3 trials recruiting
Cardiac failure · Arteriosclerosis · Cardiovascular disorder
Adult patients

About Specializations

Tonus 2013 Ltd. in Pazardzhik, Bulgaria specialises in clinical trials of conditions such as Cardiac failure, Arteriosclerosis, Cardiovascular disorder, Chronic kidney disease, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases Research

At Tonus 2013 Ltd. in Pazardzhik, the clinical trial portfolio focuses on cardiovascular diseases, with studies centered on major conditions such as heart failure, atherosclerotic cardiovascular disease, and chronic kidney disease. The research is aimed at evaluating new treatment approaches and understanding whether they can better protect patients from serious heart-related events.

Studies in heart failure are exploring whether new therapies can improve outcomes for people with weakened heart function.
Research in atherosclerotic cardiovascular disease is assessing strategies to reduce the risk of major cardiovascular events.
Trials involving chronic kidney disease are examining treatments that may also lower cardiovascular complications.

The site’s work reflects a strong interest in both prevention and treatment, with a clear emphasis on testing whether emerging therapies can improve long-term cardiovascular health.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Bulevard Tsar Osvoboditel 414400 PazardzhikBulgaria

Open in maps ↗

Recruiting now: 3 trials
Conditions studied: 6

More sites in Pazardzhik Bulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

6 clinical trials

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Chronic kidney disease+1

Recruiting

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Orforglipron hemicalcium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Cardiac failure

Recruiting

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Cardiovascular disorder

Not recruiting

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Cagrilintide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Obesity

Not recruiting

Study of KAI-9531 in Adults With Obesity or Overweight and Weight-Related Health Problems Without Diabetes

Investigational

Study of KAI-9531 in Adults With Obesity or Overweight and Weight-Related Health Problems Without Diabetes

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:HRS 9531

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites